PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

Size: px
Start display at page:

Download "PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024"

Transcription

1 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

2 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or 2

3 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels of inattention, impulsivity, and hyperactivity, either alone or in combination that have a significant social impact through disruptions at school, work, home, and in relationships. The majority of children with the disorder will continue to experience symptoms into adolescence % of children diagnosed with ADHD continue to have problems into adulthood resulting in 2-5% of adults having ADHD. Growth is expected in the global ADHD marketplace, despite the market being widely genericized. This will be driven largely by the anticipated launch of assets from the heavily populated ADHD pipeline, as these products offer clinical advantages that will drive strong uptake. Furthermore, the number of drug-treated patients will increase over the forecast period, driven by increased treatment rates throughout the 7MM, particularly in the adult age group. Highlights Key Questions Answered - The ADHD market has been dominated by stimulant therapy, with only three approved non-stimulant drugs approved that cannot compete with stimulant drugs in terms of efficacy. Due to lack of evidence for long-term safe use of stimulants, non-stimulants are becoming increasingly popular in the 7MM. Both stimulant and nonstimulant therapies are anticipated to reach the market within the forecast period. How will these change the market overall during the forecast period? Will stimulants maintain market dominance in 2024? - The current late stage ADHD pipeline is heavily populated, drugs designed to satisfy what GlobalData has identified as unmet needs. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this crowded market? - ADHD is becoming increasingly recognized, particularly n the adult population, leading to increase number in treated patients across the 7MM. How will these changes impact the growth of the future market? Key Findings - The main driver of growth in the ADHD market will be the increase in the number of drug-treated patients, driven by an increase in treatment rates expected to 2024, particularly in the adult age group. - Lack of awareness and recognition of ADHD leads to misdiagnosis; this has acted as a barrier to appropriate treatment for ADHD. - The arrival of new therapies across the 7MM will increase treatment rates and provide alternative options for 3

4 many patients, particularly those who have difficulty or who dislike swallowing pills and those who choose nonstimulant therapy. - One of the key unmet needs in the ADHD market of additional treatment options will be somewhat satisfied by the emerging pipeline assets during the forecast. Despite the increasingly competitive nature of the ADHD market, lucrative opportunities remain for products that target unmet needs. In addition, providing clinically relevant, head-to-head comparisons is an important consideration for companies developing drugs to treat these patients. Scope - Overview of ADHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized ADHD market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the ADHD therapeutics market. - Pipeline analysis: focus on 13 late-stage pipeline ADHD drugs discussing emerging trends as well as an overview of earlier phase drugs. - Analysis of the current and future market competition in the global ADHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the global ADHD therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ADHD therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global ADHD therapeutics market from Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Additional Details Publisher : Global Data 4

5 Reference : GDHC125PIDR Number of Pages : 369 Report Format : PDF Publisher Information : 5

6 Table Of Contents for PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to Table of Contents1 Table of Contents List of Tables List of Figures 242 Introduction Catalyst Related Reports Upcoming Related Reports 273 Disease Overview Etiology and Pathophysiology Etiology Pathophysiology Classification Predominantly Inattentive Type Predominantly Hyperactive-Impulsive Type Combined Type Other Specified ADHD Type Unspecified Type Severity Symptoms Prognosis 364 Epidemiology Disease Background Risk Factors and Comorbidities Global Trends US EU Japan Forecast Methodology Sources Used Tables Forecast assumptions and methods Sources Not Used Epidemiological Forecast for ADHD ( ) Diagnosed Prevalent Cases of ADHD Age-Specific Diagnosed Prevalent Cases of ADHD Sex-Specific Diagnosed Prevalent Cases of ADHD Age-Standardized Prevalence of ADHD Diagnosed Prevalent Cases of ADHD by Subtype Discussion Epidemiological Forecast Insight Limitations of the Analysis Strengths of the Analysis 765 Disease Management Diagnosis and Treatment Overview Diagnosis Treatment Guidelines and Leading Prescribed Drugs Clinical Practice US EU Japan 956 Competitive Assessment Overview Product Profiles - Amphetamine (Stimulant) Dextroamphetamine Desoxyn (methamphetamine) Adderall XR (Mixed amphetamine Salts) Vyvanse (lisdexamphetamine dimesylate) Dyanavel XR (Liquid Amphetamine XR) Adzenys XR-ODT (Amphetamine Extended Release-Orally Disintegrating Tablet) Product Profiles - Methylphenidate (Stimulant) Ritalin LA Concerta Medikinet XL Metadate CD Methylin Focalin Daytrana Quillivant XR/Quillichew Aptensio XR Product Profiles - Nonstimulants Strattera (Atomoxetine Hydrochloride) Intuniv (Guanfacine Hydrochloride) Kapvay (Clonidine) Other Therapeutic Classes 1917 Unmet Need and Opportunity Analysis Overview More Effective, Longer-Lasting, and/or Non-stimulant Treatment Options Unmet Need Gap Analysis Opportunity Clinically Relevant, Head-to-Head Comparisons Unmet Need Gap Analysis Opportunity Improved Diagnostic Tests Unmet Need Gap Analysis Opportunity Education and Recognition of ADHD Unmet Need Gap Analysis Opportunity Discontinuation and Long- Term Safety of Stimulants Unmet Need Gap Analysis Opportunity 2058 Pipeline Assessment Overview Clinical Trial Mapping Clinical Trials by Class Overview of Promising Drugs in Clinical Development Promising Amphetamine Drugs in Clinical Development NT-0201 (Liquid Amphetamine XR) SHP-465 (Triple-Bead Mixed Amphetamine Salts) HLD-100 (Dextroamphetamine MR) Amphetamine Transdermal System (Dextroamphetamine) Promising Methylphenidate Drugs in Clinical Development Cotempla XR-ODT (Extended-Release ODT Methylphenidate) Benjorna (Methylphenidate Hydrochloride MR) Promising Non-stimulant Drugs in Clinical Development SEP (Dasotraline) Centanafadine SR SPN-810 (Molindone Hydrochloride ER) SPN-812 (Viloxazine Hydrochloride) Metadoxine ER Eltoprazine CM Other Drugs in Development 2709 Current and Future Players Overview Trends in Corporate Strategy Company Profiles Shire Novartis Janssen Eli Lilly Pfizer/Tris Pharma Highland Therapeutics Market Outlook Global Markets Forecast Drivers and Barriers - Global Issues US Forecast Key Events Drivers and Barriers EU Forecast Key Events Drivers and Barriers Japan Forecast Key Events Driver and Barriers Appendix Bibliography Abbreviations Methodology Forecasting Methodology Diagnosed ADHD Patients Percent Drug-Treated Patients Launch and Patent Expiry Dates General Pricing Assumptions Individual Drug Assumptions Generic Erosion Pricing of Pipeline Agents Primary Research - KOLs Interviewed for This Report Primary Research - Prescriber Survey About the Authors Analyst Therapy Area Director Epidemiologists Managing Epidemiologists

7 Global Director of Therapy Analysis and Epidemiology About GlobalData Disclaimer 368 7

8 List Of Tables in PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to List of Tables Table 1: Classification of ADHD According to the DSM-V and ICD-10-CM 33 Table 2: Symptoms of ADHD 36 Table 3: Prognosis and Risks Associated with ADHD 37 Table 4: Risk Factors and Comorbidities for ADHD 40 Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD 44 Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages 3 17 Years 46 Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages 18 Years 47 Table 8: 7MM, Sources Not Used in Epidemiological Analysis of ADHD 61 Table 9: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages 3 Years, Select Years, Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, N (Row%), Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages 3 Years, N (Row %), Table 12: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N (Row %), Table 13: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 18 Years, Adults, N (Row %), Table 14: Rating Scales Used for ADHD 79 Table 15: Treatment Guidelines for Disease ADHD 81 Table 16: Most Prescribed Drugs for ADHD by Class in the Global Markets, Table 17: Country Profile - US 88 Table 18: Country Profile - 5EU 93 Table 19: Country Profile - Japan 98 Table 20: Leading Treatments for ADHD, Table 21: Product Profile - Dextroamphetamine 105 Table 22: Dextroamphetamine SWOT Analysis, Table 23: Global Sales Forecasts ($m) for Dextroamphetamine, Table 24: Product Profile - Desoxyn 109 Table 25: Desoxyn SWOT Analysis,

9 Table 26: Global Sales Forecasts ($m) for Desoxyn, Table 27: Product Profile - Adderall XR 113 Table 28: Adderall XR SWOT Analysis, Table 29: Global Sales Forecasts ($m) for Adderall XR, Table 30: Product Profile - Vyvanse 119 Table 31: Vyvanse SWOT Analysis, Table 32: Global Sales Forecasts ($m) for Vyvanse, Table 33: Product Profile - Dyanavel XR 123 Table 34: Dyanavel SWOT Analysis, Table 35: Global Sales Forecasts ($m) for Dyanavel XR, Table 36: Product Profile - Adzenys XR-ODT 128 Table 37: Adzenys XR-ODT SWOT Analysis, Table 38: Global Sales Forecasts ($m) for Adzenys XR-ODT, Table 39: Product Profile - Ritalin LA 134 Table 40: Ritalin LA SWOT Analysis, Table 41: Global Sales Forecasts ($m) for Ritalin LA, Table 42: Product Profile - Concerta 138 Table 43: Concerta SWOT Analysis, Table 44: Global Sales Forecasts ($m) for Concerta, Table 45: Product Profile - Medikinet XL 143 Table 46: Medikinet SWOT Analysis, Table 47: Global Sales Forecasts ($m) for Medikinet XL, Table 48: Product Profile - Metadate CD 148 Table 49: Incidence of TEAEs in a Pool of 3-4 Week Clinical Trials - Metadate CD 149 Table 50: Metadate CD SWOT Analysis, Table 51: Global Sales Forecasts ($m) for Metadate CD, Table 52: Product Profile - Methylin 152 Table 53: Methylin SWOT Analysis, Table 54: Global Sales Forecasts ($m) for Methylin, Table 55: Product Profile - Focalin 155 Table 56: TEAEs - Focalin 157 9

10 Table 57: TEAEs - Focalin XR 157 Table 58: Focalin SWOT Analysis, Table 59: Global Sales Forecasts ($m) for Focalin and Focalin XR, Table 60: Product Profile - Daytrana 160 Table 61: Daytrana SWOT Analysis, Table 62: Global Sales Forecasts ($m) for Daytrana, Table 63: Product Profile - Quillivant XR 164 Table 64: Quillichew Primary Efficacy Result 165 Table 65: Quillivant XR SWOT Analysis, Table 66: Global Sales Forecasts ($m) for Quillivant XR/Quillichew, Table 67: Product Profile - Aptensio XR 168 Table 68: Summary of the Parallel Group Study - Aptensio XR 169 Table 69: Aptensio XR SWOT Analysis, Table 70: Global Sales Forecasts ($m) for Aptensio XR, Table 71: Product Profile - Strattera 174 Table 72: Acute and Maintenance Efficacy Studies - Strattera 176 Table 73: Common TEAEs reported in acute trials in children and adolescents - Strattera 178 Table 74: Common TEAEs reported in acute trials in adults - Strattera 179 Table 75: Strattera SWOT Analysis, Table 76: Global Sales Forecasts ($m) for Strattera, Table 77: Product Profile - Intuniv 183 Table 78: Fixed Dose Studies- Intuniv 184 Table 79: Intuniv SWOT Analysis, Table 80: Global Sales Forecasts ($m) for Intuniv, Table 81: Product Profile - Kapvay 188 Table 82: Kapvay SWOT Analysis, Table 83: Global Sales Forecasts ($m) for Kapvay, Table 84: Unmet Need and Opportunity in ADHD 194 Table 85: Drugs in Development, Table 86: Comparison of Therapeutic Classes in Development for ADHD, Table 87: Product Profile - Liquid Amphetamine XR, NT

11 Table 88: NT-0201 SWOT Analysis, Table 89: Global Sales Forecasts ($m) for NT-0201, Table 90: Product Profile - Triple-Bead Mixed Amphetamine Salts (SHP-465) 216 Table 91: SHP-465 SWOT Analysis, Table 92: Global Sales Forecasts ($m) for SHP-465, Table 93: Product Profile - HLD Table 94: HLD-100 SWOT Analysis, Table 95: Global Sales Forecasts ($m) for HLD-100, Table 96: Product Profile - Dextroamphetamine Transdermal Patch 226 Table 97: Dextroamphetamine Transdermal Patch SWOT Analysis, Table 98: Global Sales Forecasts ($m) for ATS, Table 99: Product Profile - Cotempla XR-ODT 230 Table 100: Cotempla XR-ODT SWOT Analysis, Table 101: Global Sales Forecasts ($m) for Cotempla XR-ODT, Table 102: Product Profile - Benjorna 234 Table 103: Benjorna SWOT Analysis, Table 104: Global Sales Forecasts ($m) for Benjorna, Table 105: Product Profile - Dasotraline 239 Table 106: Dasotraline SWOT Analysis, Table 107: Global Sales Forecasts ($m) for dasotraline, Table 108: Product Profile - Centanafadine SR 244 Table 109: Centanafadine SR SWOT Analysis, Table 110: Global Sales Forecasts ($m) for centanafadine SR, Table 111: Product Profile - SPN Table 112: SPN-810 SWOT Analysis, Table 113: Global Sales Forecasts ($m) for SPN-810, Table 114: Product Profile - Viloxazine 253 Table 115: Viloxazine SWOT Analysis, Table 116: Global Sales Forecasts ($m) for Pipeline Viloxazine, Table 117: Product Profile - Metadoxine ER 258 Table 118: Metadoxine ER SWOT Analysis,

12 Table 119: Global Sales Forecasts ($m) for Metadoxine ER, Table 120: Product Profile - Eltoprazine 263 Table 121: Eltoprazine SWOT Analysis, Table 122: Global Sales Forecasts ($m) for Eltoprazine, Table 123: Product Profile - CM Table 124: CM-4612 SWOT Analysis, Table 125: Global Sales Forecasts ($m) for CM-4612, Table 126: Drugs in Development, Table 127: Key Companies in the ADHD Market in the 7MM, Table 128: Shire s ADHD Portfolio Assessment, Table 129: Novartis ADHD Portfolio Assessment, Table 130: Janssen s ADHD Portfolio Assessment, Table 131: Eli Lilly s ADHD Portfolio Assessment, Table 132: Pfizer/Tris Pharma s ADHD Portfolio Assessment, Table 133: Highland Therapeutics ADHD Portfolio Assessment, Table 134: Global Sales Forecasts ($m) for ADHD, Table 135: ADHD Market - Global Drivers and Barriers, Table 136: Sales Forecasts ($m) for ADHD in the US, Table 137: Key Events Impacting Sales for ADHD in the US, Table 138: ADHD Market - Drivers and Barriers in the US, Table 139: Sales Forecasts ($m) for ADHD in the 5EU, Table 140: Key Events Impacting Sales for ADHD in the 5EU, Table 141: ADHD Market - Drivers and Barriers in the 5EU, Table 142: Sales Forecasts ($m) for ADHD in Japan, Table 143: Key Events Impacting Sales for ADHD in Japan, Table 144: ADHD Market - Drivers and Barriers in Japan, Table 145: Key ADHD Launch Dates 350 Table 146: Key ADHD Patent Expiries 350 Table 147: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country,

13 List Of Figures, Charts and Diagrams in PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to List of Figures Figure 1: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages 3 Years, Selected Years, Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages 3 Years, Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of ADHD, Ages 3 Years, Figure 5: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N, Figure 6: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 18 Years, Adults, N, Figure 7: Treatment Algorithm for ADHD in the 7MM 80 Figure 8: ADHD Therapeutics - Class of Therapy, Figure 9: ADHD - Phase II-III Pipeline, Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in ADHD, Figure 11: Clinical and Commercial Positioning of NT Figure 12: Clinical and Commercial Positioning of SHP Figure 13: Clinical and Commercial Positioning of HLD Figure 14: Clinical and Commercial Positioning of ATS 227 Figure 15: Clinical and Commercial Positioning of Cotempla XR-ODT 231 Figure 16: Clinical and Commercial Positioning of Benjorna 236 Figure 17: Clinical and Commercial Positioning of Dasotraline 241 Figure 18: Clinical and Commercial Positioning of Centanafadine SR 245 Figure 19: Clinical and Commercial Positioning of SPN Figure 20: Clinical and Commercial Positioning of Viloxazine 254 Figure 21: Clinical and Commercial Positioning of Metadoxine ER 260 Figure 22: Clinical and Commercial Positioning of Eltoprazine 264 Figure 23: Clinical and Commercial Positioning of CM Figure 24: Global Sales of Branded Products for ADHD by Company, Figure 25: Company Portfolio Gap Analysis in ADHD, Figure 26: Shire SWOT Analysis in ADHD,

14 Figure 27: Novartis SWOT Analysis in ADHD, Figure 28: Janssen SWOT in ADHD, Figure 29: Eli Lilly SWOT Analysis in ADHD, Figure 30: Pfizer/Tris Pharma SWOT Analysis in ADHD, Figure 31: Highland Therapeutics SWOT Analysis in ADHD, Figure 32: Global Sales for ADHD by Country, 2014 and Figure 33: Global Sales for ADHD by Drug Class, 2014 and Figure 34: Sales for ADHD by Drug Class in the US, 2014 and Figure 35: Sales for ADHD by Drug Class in the 5EU, 2014 and Figure 36: Sales for ADHD by Drug Class in Japan, 2014 and

15 How to Buy... PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $10995 Single User Price $21990 Site License Price $32985 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 15

Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024

Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research reports

More information

Bariatric Surgery Devices - North America Analysis and Market Forecasts

Bariatric Surgery Devices - North America Analysis and Market Forecasts Bariatric Surgery Devices - North America Analysis and Market Forecasts Bariatric Surgery Devices - North America Analysis and Market Forecasts BioPortfolio has been marketing business and market research

More information

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research

More information

Russia Cardiac Assist Devices Market Outlook to 2021

Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 BioPortfolio has been marketing business and market research reports from selected publishers for

More information

North America Cardiac Rhythm Management (CRM) Procedures Outlook to 2021

North America Cardiac Rhythm Management (CRM) Procedures Outlook to 2021 North America Cardiac Rhythm Management (CRM) Procedures Outlook to 2021 North America Cardiac Rhythm Management (CRM) Procedures Outlook to 2021 BioPortfolio has been marketing business and market research

More information

HER2-Negative Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

HER2-Negative Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 HER2-Negative Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 HER2-Negative Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 BioPortfolio has been marketing business and market

More information

Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016

Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016 Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016 Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016 BioPortfolio has been marketing business

More information

Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase

More information

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 BioPortfolio

More information

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon),

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin,

More information

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports

More information

Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment

Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment BioPortfolio has been marketing business

More information

Sickle-cell Anemia Therapeutics Market in the US

Sickle-cell Anemia Therapeutics Market in the US Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sector Publishing Intelligence Limited (SPi) has been marketing business and market

More information

Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment

Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment BioPortfolio has been marketing

More information

Infertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer,

Infertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer, Infertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer, Workstation), Technology (AI, Gamete Donation, IVF, ICSI,

More information

Cochlear Implants - Medical Devices Pipeline Assessment, 2016

Cochlear Implants - Medical Devices Pipeline Assessment, 2016 Cochlear Implants - Medical Devices Pipeline Assessment, 2016 Cochlear Implants - Medical Devices Pipeline Assessment, 2016 BioPortfolio has been marketing business and market research reports from selected

More information

Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic

Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic Cancer, Others (Cirrhosis, and Hepatitis)) & Geography-Forecast

More information

Australia Dental Implants And Prosthetics Market By Implant Material (Titanium, Zirconium), Prosthetic Product (Bridges, Crowns, Dentures), Denture

Australia Dental Implants And Prosthetics Market By Implant Material (Titanium, Zirconium), Prosthetic Product (Bridges, Crowns, Dentures), Denture Australia Dental Implants And Prosthetics Market By Implant Material (Titanium, Zirconium), Prosthetic Product (Bridges, Crowns, Dentures), Denture Type (Partial,Complete), and Abutment Type (Definitive,

More information

Urinary Incontinence Products Market in Europe

Urinary Incontinence Products Market in Europe Urinary Incontinence Products Market in Europe 2015-2019 Urinary Incontinence Products Market in Europe 2015-2019 BioPortfolio has been marketing business and market research reports from selected publishers

More information

Global In-Vitro-Fertilization Market: Trends and Opportunities ( )

Global In-Vitro-Fertilization Market: Trends and Opportunities ( ) Global In-Vitro-Fertilization Market: Trends and Opportunities (2015-2019) Global In-Vitro-Fertilization Market: Trends and Opportunities (2015-2019) BioPortfolio has been marketing business and market

More information

Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter

Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS), and Cardiac Resynchronization

More information

China Silymarin Industry Overview,

China Silymarin Industry Overview, China Silymarin Industry Overview, 2017-2021 China Silymarin Industry Overview, 2017-2021 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen

More information

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 BioPortfolio has been marketing business

More information

Percutaneous Transluminal Angioplasty Balloons - Medical Devices Pipeline Assessment, 2016

Percutaneous Transluminal Angioplasty Balloons - Medical Devices Pipeline Assessment, 2016 Percutaneous Transluminal Angioplasty Balloons - Medical Devices Pipeline Assessment, 2016 Percutaneous Transluminal Angioplasty Balloons - Medical Devices Pipeline Assessment, 2016 BioPortfolio has been

More information

Silica Fume Market by Application (Building Construction, Marine Structure Construction, Oil & Gas Well Grouting, Nuclear Power Plant Construction,

Silica Fume Market by Application (Building Construction, Marine Structure Construction, Oil & Gas Well Grouting, Nuclear Power Plant Construction, Silica Fume Market by Application (Building Construction, Marine Structure Construction, Oil & Gas Well Grouting, Nuclear Power Plant Construction, Chemical Production Facilities Construction, by Geography

More information

Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics

Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth

More information

Global Insulin Pumps Market

Global Insulin Pumps Market Global Insulin Pumps Market 2016-2020 Global Insulin Pumps Market 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio

More information

Structural Heart Devices Market by Product (Structural Heart Repair Devices and Replacement Valves), Age Group (Pediatric and Adult), and Indication

Structural Heart Devices Market by Product (Structural Heart Repair Devices and Replacement Valves), Age Group (Pediatric and Adult), and Indication Structural Heart Devices Market by Product (Structural Heart Repair Devices and Replacement Valves), Age Group (Pediatric and Adult), and Indication (Atrial Septal Defect (ASD), Patent Foramen Ovale (PFO),

More information

EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET FORECAST

EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET FORECAST EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET FORECAST 2017-2025 EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET FORECAST 2017-2025 BioPortfolio has been marketing business and market research reports

More information

Global Vitamin Ingredients Market

Global Vitamin Ingredients Market Global Vitamin Ingredients Market 2016-2020 Global Vitamin Ingredients Market 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years.

More information

Aesthetic Laser - Medical Devices Pipeline Assessment, 2016

Aesthetic Laser - Medical Devices Pipeline Assessment, 2016 Aesthetic Laser - Medical Devices Pipeline Assessment, 2016 Aesthetic Laser - Medical Devices Pipeline Assessment, 2016 BioPortfolio has been marketing business and market research reports from selected

More information

Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile

Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global

COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and

More information

Proton Therapy Market Outlook - Global Analysis

Proton Therapy Market Outlook - Global Analysis Proton Therapy Market Outlook - Global Analysis Proton Therapy Market Outlook - Global Analysis BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen

More information

Invisible Orthodontics Market in China

Invisible Orthodontics Market in China Invisible Orthodontics Market in China 2016-2020 Invisible Orthodontics Market in China 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers for over

More information

Global Avian Influenza Vaccines Market Data Survey Report 2025

Global Avian Influenza Vaccines Market Data Survey Report 2025 Global Avian Influenza Vaccines Market Data Survey Report 2025 Global Avian Influenza Vaccines Market Data Survey Report 2025 BioPortfolio has been marketing business and market research reports from selected

More information

Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022

Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton

More information

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare

More information

Phone: +44 (0) or BioPortfolio Limited

Phone: +44 (0) or   BioPortfolio Limited Europe Neuromodulation Devices Market by Procedure [Internal Stimulation (DBS, GES, SNS, SCS, VNS), and External Stimulation (TENS, TMS)], and by Geography Analysis & Forecast to 2019 Europe Neuromodulation

More information

Diabetic Neuropathy - Pipeline Review, H1 2017

Diabetic Neuropathy - Pipeline Review, H1 2017 Diabetic Neuropathy - Pipeline Review, H1 2017 Diabetic Neuropathy - Pipeline Review, H1 2017 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen

More information

Poultry Diagnostics Market by Test (ELISA, PCR) Disease (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Pasteurellosis,

Poultry Diagnostics Market by Test (ELISA, PCR) Disease (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Pasteurellosis, Poultry Diagnostics Market by Test (ELISA, PCR) Disease (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Pasteurellosis, Encephalomyelitis, Infectious Bronchitis), Service (Virology, Bacteriology,

More information

Sukhjit Starch And Chemicals Ltd - Company Capsule

Sukhjit Starch And Chemicals Ltd - Company Capsule Sukhjit Starch And Chemicals Ltd - Company Capsule Sukhjit Starch And Chemicals Ltd - Company Capsule The Business Research Store is run by Sector Publishing Intelligence Ltd. SPi has been selling professional

More information

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),

More information

QUANTITY LIMIT CRITERIA

QUANTITY LIMIT CRITERIA DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS

More information

GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy

GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine

More information

REFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for cariprazine in the Major Depressive Disorder (MDD)

More information

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business

More information

Central Nervous System Stimulants Drug Class Prior Authorization Protocol

Central Nervous System Stimulants Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through

More information

REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for brexpiprazole in the Major Depressive Disorder

More information

Global Hepatitis B and C Diagnostics Market

Global Hepatitis B and C Diagnostics Market Global Hepatitis B and C Diagnostics Market 2016-2020 Global Hepatitis B and C Diagnostics Market 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers

More information

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE: DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Brintellix in the seven major pharmaceutical markets

More information

REFERENCE CODE GDHC423DFR PUBLICAT ION DATE M AY 2014 ABILIFY (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC423DFR PUBLICAT ION DATE M AY 2014 ABILIFY (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC423DFR PUBLICAT ION DATE M AY 2014 ABILIFY (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Abilify in the seven major pharmaceutical markets

More information

REFERENCE CODE GDHC420DFR PUBLICAT ION DATE M AY 2014 FETZIMA (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC420DFR PUBLICAT ION DATE M AY 2014 FETZIMA (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC420DFR PUBLICAT ION DATE M AY 2014 FETZIMA (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Fetzima in the seven major pharmaceutical markets

More information

United States Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022

United States Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 United States Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 United States Proton Therapy Market (Actual & Potential), Patients Treated,

More information

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019 Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general

More information

Parents Guide to ADHD Medications. Copyright Child Mind Institute

Parents Guide to ADHD Medications. Copyright Child Mind Institute Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive

More information

AD/HD is a mental disorder, and it often lasts from

AD/HD is a mental disorder, and it often lasts from short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.

More information

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,

More information

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) Executive Summary Table below provides a summary of the key metrics for Cariprazine in the seven major pharmaceutical

More information

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

ADHD Medications Table

ADHD Medications Table Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common

More information

REFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA US DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA US DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA Executive Summary Schizophrenia Sales in the US, 2012 The combined sales of medications carrying an indication in schizophrenia in

More information

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6 in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,

More information

REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013

More information

ADHD Stimulant Step Therapy Program

ADHD Stimulant Step Therapy Program ADHD Stimulant Step Therapy Program Policy Number: 5.01.592 Last Review: 7/2018 Origination: 7/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of AstraZeneca/Ardelyx s tenapanor for Irritable

More information

Cerebral Stimulant and ADHD Drugs Prior Authorization Request

Cerebral Stimulant and ADHD Drugs Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 Cerebral Stimulant and ADHD Drugs Prior Authorization

More information

REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Sales for Parkinson s Disease in the US The Parkinson s disease market in the

More information

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid Clinical Policy: Reference Number: CP.PMN.XX Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Parkinson s Disease in Japan Market The Parkinson

More information

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major

More information

ADHD Medications: Basics. David Benhayon MD, PhD

ADHD Medications: Basics. David Benhayon MD, PhD ADHD Medications: Basics David Benhayon MD, PhD Goals & Objectives Understand basic classes of stimulants and equivalents Be exposed to role of nonstimulant alternatives Discuss the role of therapy in

More information

Clinical Policy: Atomoxetine (Strattera) Reference Number: CP.PST.17 Effective Date:

Clinical Policy: Atomoxetine (Strattera) Reference Number: CP.PST.17 Effective Date: Clinical Policy: (Strattera) Reference Number: CP.PST.17 Effective Date: 08.01.17 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative

More information

REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Prometheus Lotronex for irritable bowel syndrome

More information

REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Furiex (Actavis) s eluxadoline for Irritable

More information

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India

More information

REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS

REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - Executive Summary Human PapillomaVirus (HPV) Vaccine Sales Expected to Grow Modestly During the Forecast

More information

REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - Executive Summary Botox: Key Metrics in the 7MM* for Migraine, 2012-2023 2012 Market Sales US $434.3m 5 EU $68.3m Japan Total

More information

REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Stalevo/Comtan in the 8MM Parkinson

More information

35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.

35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)

More information

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m

More information

REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS

REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - Executive Summary Meningococcal Vaccines: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Epidemiology Targeted

More information

REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG Executive Summary Sales for Chronic Heart Failure in the Japan The Japan Chronic heart failure (CHF) therapeutics

More information

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012

More information

Insulin Pens - Medical Devices Pipeline Assessment, 2016

Insulin Pens - Medical Devices Pipeline Assessment, 2016 Insulin Pens - Medical Devices Pipeline Assessment, 2016 Insulin Pens - Medical Devices Pipeline Assessment, 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business and market research

More information

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.92 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.92 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid Clinical Policy: Reference Number: CP.PMN.92 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML) Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is

More information

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - Executive Summary Menomune: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU

More information

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) Executive Summary Nimenrix: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan

More information

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India

More information

REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - India Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in India 2012 We estimate the 2012 PsO drug

More information

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets

More information

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical

More information

REFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - Executive Summary The Table below presents the key metrics of Ironwood/Actavis/Almirall/Astellas Linzess for

More information

REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Nouriast in the 8MM Parkinson s Disease

More information